A
Alphonse G. Taghian
Researcher at Harvard University
Publications - 331
Citations - 13907
Alphonse G. Taghian is an academic researcher from Harvard University. The author has contributed to research in topics: Breast cancer & Radiation therapy. The author has an hindex of 58, co-authored 313 publications receiving 11945 citations. Previous affiliations of Alphonse G. Taghian include University of Florence & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
Paul L. Nguyen,Alphonse G. Taghian,Matthew S. Katz,Andrzej Niemierko,Rita Abi Raad,Whitney L. Boon,Jennifer R. Bellon,Julia S. Wong,Barbara L. Smith,Jay R. Harris +9 more
TL;DR: Overall, the 5-year local recurrence rate after BCT was low, but varied by subtype as approximated using ER, PR, and HER-2 status, which may be useful in counseling patients about their anticipated outcome after B CT.
Journal ArticleDOI
Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement.
C Correa,Eleanor E.R. Harris,Maria Cristina Leonardi,Benjamin Smith,Alphonse G. Taghian,Alastair M. Thompson,Julia White,Jay R. Harris +7 more
TL;DR: Recommendations for the use of IORT for breast cancer patients include: counseling patients regarding the higher risk of ipsilateral breast tumor recurrence with IORT compared with whole breast irradiation; the need for prospective monitoring of long-term local control and toxicity with low-energy radiograph IORT given limited follow-up.
Journal ArticleDOI
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Eleftherios P. Mamounas,Stewart J. Anderson,James J. Dignam,Harry D. Bear,Thomas B. Julian,Charles E. Geyer,Alphonse G. Taghian,D. Lawrence Wickerham,Norman Wolmark +8 more
TL;DR: In patients treated with NC, age, clinical tumor characteristics before NC, and pathologic nodal status/breast tumor response after NC can be used to predict risk for LRR and to optimize the use of adjuvant radiotherapy.
Journal ArticleDOI
Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy
Nils D. Arvold,Alphonse G. Taghian,Andrzej Niemierko,Rita Abi Raad,Meera Sreedhara,Paul L. Nguyen,Jennifer R. Bellon,Julia S. Wong,Barbara L. Smith,Jay R. Harris +9 more
TL;DR: In the era of systemic therapy and BC subtyping, age remains an independent prognostic factor after BCT, however, the risk of LR for young women appears acceptably low.
Journal ArticleDOI
Prospective Comparison of Mammography, Sonography, and MRI in Patients Undergoing Neoadjuvant Chemotherapy for Palpable Breast Cancer
Eren D. Yeh,Priscilla J. Slanetz,Daniel B. Kopans,Elizabeth A. Rafferty,Dianne Georgian-Smith,Linda Moy,Elkan F. Halpern,Richard D. Moore,Irene Kuter,Alphonse G. Taghian +9 more
TL;DR: MRI appears to provide the best correlation with pathology-better than physical examination, mammography, and sonography-in patients undergoing neoadjuvant chemotherapy, however, MRI may overestimate or underestimate residual disease in approximately 29% of the patients (95% confidence interval, 14-48%).